Annexon (ANNX)
(Delayed Data from NSDQ)
$2.45 USD
+0.05 (2.08%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.46 +0.01 (0.41%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ANNX 2.45 +0.05(2.08%)
Will ANNX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANNX
New Strong Sell Stocks for July 22nd
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
ANNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ANNX
Annexon (ANNX) Completes Enrollment for Phase 3 Trial of Vonaprument | ANNX Stock News
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument ...
Annexon completes enrollment in Phase 3 ARCHER II trial
Annexon: Lead GBS Therapy Stokes Near-Term Potential
Annexon tells Wells Fargo doctor tweet not factural